Compare · RCLF vs RMD
RCLF vs RMD
Side-by-side comparison of Rosecliff Acquisition Corp I (RCLF) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RCLF and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $34.07B, about 109.8x RCLF ($310.2M).
- RMD has hit the wire 9 times in the past 4 weeks while RCLF has been quiet.
- RMD has more recent analyst coverage (25 ratings vs 0 for RCLF).
- Company
- Rosecliff Acquisition Corp I
- ResMed Inc.
- Price
- -
- -
- Market cap
- $310.2M
- $34.07B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 9
- Recent ratings
- 0
- 25
Rosecliff Acquisition Corp I
Rosecliff Acquisition Corp I, a blank check company, focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization/similar business combination with one or more businesses. The company was incoporated in 2020 and is based in New York, New York.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest RCLF
- Rosecliff Acquisition Corp I filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Rosecliff Acquisition Corp I filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form S-8 filed by Rosecliff Acquisition Corp I
- SEC Form SC 13G filed by Rosecliff Acquisition Corp I
- Rosecliff Acquisition Corp I filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Rosecliff Acquisition Corp I filed SEC Form 8-K: Leadership Update
- SEC Form EFFECT filed by Rosecliff Acquisition Corp I
- SEC Form 424B3 filed by Rosecliff Acquisition Corp I
- SEC Form S-1/A filed by Rosecliff Acquisition Corp I (Amendment)
- SEC Form S-1 filed by Rosecliff Acquisition Corp I
Latest RMD
- SEC Form 4 filed by ResMed Inc.
- SEC Form DEFA14A filed by ResMed Inc.
- SEC Form DEF 14A filed by ResMed Inc.
- Amendment: SEC Form 4 filed by Chairman and CEO Farrell Michael J.
- Chief Product Officer Leong Justin was granted 6,461 units of ResMed Common Stock, increasing direct ownership by 22% to 35,489 units (SEC Form 4)
- Global General Counsel Rider Michael J was granted 3,230 units of ResMed Common Stock, increasing direct ownership by 34% to 12,718 units (SEC Form 4)
- Chairman and CEO Farrell Michael J. was granted 13,547 units of ResMed Common Stock, increasing direct ownership by 3% to 479,803 units (SEC Form 4)
- Chief Financial Officer Bloomer Aaron was granted 9,072 units of ResMed Common Stock (SEC Form 4)
- Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
- ResMed upgraded by RBC Capital Mkts with a new price target